Document Detail


Case-control study of screening for prostatic cancer by digital rectal examinations.
MedLine Citation:
PMID:  1675379     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Although commonly thought to be an effective method of screening for prostatic cancer, digital rectal examinations have yet to be shown by controlled study to help prevent advanced forms of this disease. 139 men with metastatic (stage D) prostatic cancer (cases) were compared with an equal number of matched men free of this condition (controls), with respect to rectal examinations recorded in the medical records up to, on average, 23 years before the cases' initial diagnosis of prostatic cancer. Cases and controls were members of a large health maintenance organisation in northern California. In the 10 years before initial diagnosis (excluding the last three months) the average number of examinations for routine screening (2.45 vs 2.52) or to evaluate intestinal or rectal symptoms (0.44 in both) were similar in cases and controls, respectively. After adjustment for racial differences, the relative risk of metastatic prostatic cancer for men with one or more screening rectal examinations compared with men with none was 0.9 with a 95% confidence interval of 0.5-1.7. Screening by routine digital rectal examination appears to have little if any effect in preventing metastatic prostatic cancer. If there is a small benefit, it will be difficult to demonstrate by conventional epidemiological study.
Authors:
G D Friedman; R A Hiatt; C P Quesenberry; J V Selby
Related Documents :
21193489 - Weekly paclitaxel combining with gemcitabine is an effective and safe treatment for adv...
7519789 - Voluntary screening program for prostate cancer: detection rate and cost.
7529409 - Screening for prostate cancer.
16397859 - A population model of prostate cancer incidence.
9351559 - The early detection of prostate carcinoma with prostate specific antigen: the washingto...
15054989 - Racgp training registrars' perceptions and practice of prostate cancer screening.
22595929 - Mondor's disease in a patient previously treated for breast carcinoma in situ: a case r...
19004009 - Endoglin (cd105) as a urinary and serum marker of prostate cancer.
20705559 - Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in ...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  Lancet     Volume:  337     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  1991 Jun 
Date Detail:
Created Date:  1991-07-18     Completed Date:  1991-07-18     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1526-9     Citation Subset:  AIM; IM    
Affiliation:
Division of Research, Kaiser Permanente Medical Care Program, Oakland, California.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
California / epidemiology
Evaluation Studies as Topic
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Metastasis
Palpation / methods*
Prostatic Neoplasms / diagnosis*,  epidemiology,  pathology,  prevention & control
Rectum
Retrospective Studies
Risk Factors
Comments/Corrections
Comment In:
Lancet. 1991 Sep 28;338(8770):819   [PMID:  1681183 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Classification and natural history of clinically identifiable subtypes of cerebral infarction.
Next Document:  Prolonged administration in vivo of alpha and beta adrenergic agonists decreases insulin binding to ...